Inventiva (IVA) News Today $2.35 -0.02 (-0.84%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Inventiva to present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 17, 2024 | globenewswire.comInventiva S.A. Boosts Capital with New Share and Warrant IssuanceDecember 17, 2024 | markets.businessinsider.comInventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 millionDecember 16, 2024 | globenewswire.comInventiva Shareholders’ Meeting Approves Key ResolutionsDecember 12, 2024 | markets.businessinsider.comResults of the votes of the Combined Shareholders' General Meeting of December 11, 2024December 12, 2024 | globenewswire.comInventiva Plans Strategic Moves at Upcoming 2024 MeetingNovember 26, 2024 | markets.businessinsider.comInventiva price target lowered to $17 from $20 at StifelNovember 23, 2024 | markets.businessinsider.comStifel Nicolaus Has Lowered Expectations for Inventiva (NASDAQ:IVA) Stock PriceStifel Nicolaus reduced their price target on shares of Inventiva from $20.00 to $17.00 and set a "buy" rating on the stock in a research report on Friday.November 22, 2024 | marketbeat.comINVENTIVA: Inventiva reports 2024 Third Quarter Financial InformationNovember 22, 2024 | finanznachrichten.deInventiva reports revenues for irst nine months FY24 EUR 1.3MNovember 22, 2024 | markets.businessinsider.comInventiva’s Financial Position and Future ProspectsNovember 22, 2024 | markets.businessinsider.comInventiva reports 2024 Third Quarter Financial Information¹November 21, 2024 | globenewswire.comInventiva Prepares for Key General Meeting and Financing PlansNovember 21, 2024 | markets.businessinsider.comInventiva Reports Voting Rights and Advances Clinical TrialsNovember 21, 2024 | markets.businessinsider.comCombined General Meeting of December 11, 2024 - Availability of the preparatory documentsNovember 20, 2024 | globenewswire.comThe first MASH drug could open the door for others — including GLP-1sNovember 18, 2024 | finance.yahoo.comInventiva’s Phase 2 Results Boost Hope for MASH TreatmentNovember 15, 2024 | markets.businessinsider.comInventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker sessionNovember 15, 2024 | globenewswire.comInventiva S.A. Plans Key Shareholder Meeting in DecemberNovember 15, 2024 | markets.businessinsider.comCautious Optimism for Inventiva’s Lanifibranor Amidst Execution Challenges and Dilution RisksNovember 13, 2024 | markets.businessinsider.comInventiva initiated with a Neutral at UBSNovember 13, 2024 | markets.businessinsider.comInventiva (NASDAQ:IVA) Coverage Initiated by Analysts at UBS GroupUBS Group began coverage on Inventiva in a research report on Tuesday. They set a "neutral" rating and a $3.00 price target for the company.November 12, 2024 | marketbeat.comInventiva Gains Positive Nod for Lanifibranor TrialOctober 31, 2024 | markets.businessinsider.comInventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASHOctober 30, 2024 | globenewswire.comInventiva S.A. (NASDAQ:IVA) Short Interest UpdateInventiva S.A. (NASDAQ:IVA - Get Free Report) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 853,400 shares, an increase of 562.1% from the September 30th total of 128,900 shares. Based on an average daily trading volume, of 201,000 shares, the days-to-cover ratio is presently 4.2 days.October 25, 2024 | marketbeat.comInventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024October 21, 2024 | globenewswire.comFY2026 EPS Forecast for Inventiva Increased by AnalystInventiva S.A. (NASDAQ:IVA - Free Report) - Equities researchers at HC Wainwright raised their FY2026 earnings per share estimates for Inventiva in a note issued to investors on Tuesday, October 15th. HC Wainwright analyst E. Arce now expects that the company will earn ($2.43) per share for the yOctober 18, 2024 | marketbeat.comInventiva Secures €348 Million Financing, Reinforcing Buy Rating Amid Strategic AdvancementsOctober 16, 2024 | markets.businessinsider.comInventiva Shares Surge In Pre-market After Securing Finance To Advance NATiV3 Phase 3 MASH StudyOctober 14, 2024 | markets.businessinsider.comWhy Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?October 14, 2024 | finance.yahoo.comInventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrantsOctober 14, 2024 | globenewswire.comInventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the ReportOctober 14, 2024 | finance.yahoo.comInventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the ReportOctober 14, 2024 | globenewswire.comInventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH studyOctober 14, 2024 | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: Aytu BioScience (AYTU), Inventiva (IVA)September 29, 2024 | markets.businessinsider.comInventiva (NASDAQ:IVA) Stock Quotes, Forecast and News SummarySeptember 28, 2024 | benzinga.comInventiva (NASDAQ:IVA) Given New $14.00 Price Target at HC WainwrightHC Wainwright cut their target price on shares of Inventiva from $22.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday.September 26, 2024 | marketbeat.comINVENTIVA: Inventiva provides a corporate update and reports its unaudited 2024 first-half financial resultsSeptember 25, 2024 | finanznachrichten.deInventiva provides a corporate update and reports its unaudited 2024 first-half financial resultsSeptember 25, 2024 | globenewswire.comGH Research PLC (1KA.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comBioXcel Therapeutics, Inc. (BX2.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comEarnings week ahead: Micron, Costco, BlackBerry, Accenture and moreSeptember 22, 2024 | msn.comAkero Therapeutics: Good Candidate For The MASH BasketSeptember 20, 2024 | seekingalpha.comInventiva (NASDAQ:IVA) Trading Down 5.2%Inventiva (NASDAQ:IVA) Stock Price Down 5.2%August 31, 2024 | marketbeat.comStifel Nicolaus Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)August 15, 2024 | markets.businessinsider.comINVENTIVA: Inventiva Reports Preliminary 2024 First-Half Financial InformationAugust 1, 2024 | finanznachrichten.deInventiva Reports Preliminary 2024 First-Half Financial Information¹July 31, 2024 | globenewswire.comINVENTIVA: Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranorJuly 25, 2024 | finanznachrichten.deInventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranorJuly 25, 2024 | globenewswire.comINVENTIVA: Inventiva announces a €20.1 million issuance of royalty certificatesJuly 19, 2024 | finanznachrichten.de Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it. Click here to watch this demo and decide for yourself. IVA Media Mentions By Week IVA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IVA News Sentiment▼0.360.60▲Average Medical News Sentiment IVA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IVA Articles This Week▼32▲IVA Articles Average Week Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ABVX News Today MGTX News Today RNAC News Today GLUE News Today ESPR News Today TKNO News Today CDXC News Today ORGO News Today ZVRA News Today VERV News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IVA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inventiva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
